Gideon Halperin, The Sythesis of Polyunsaturated . . . Triated at C-2, Journal of Labelled Compounds and Radiopharmaceuticals, vol. XX, No. 2, Feb. 1983, pp269-275.* |
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, 1992, pp. 15-22.* |
Mechoulam et al., Identification of . . . Cannabinoid Receptors, Biochemical Pharmacology, vol. 50, No. 1, Jun. 1995, pp. 83-90.* |
J.G. Turcotte: “Synthesis of Lysophosphatidylethanolamine Analogs that Inhibit Renin Activity” Journal of Medicinal Chemistry, vol. 18, No. 12, Dec. 1975, pp. 1184-1190, XP002109045, Washington, US, p. 1189, col. 1, Table I. |
F.R. Pfeiffer; “Lysophosphatidylethanolamine and 2-desoxylysophosphatidylethanolamine Derivatives. 1. Potential Renin Inhibitors” Journal of Medicinal Chemistry, vol. 14, No. 6, Jun. 1971, pp. 493-499, XP002109046, Washington, US; Tables V and VI, Compounds 12c and 13c. |
J.R. Surles: “Facile Synthesis of Platelet-Activating Factor and Racemic Analogues Containing Unsaturation in the sn-1-alkyl chain” Journal of Medicinal Chemistry, vol. 28, No. 1, Jan. 1985, pp. 73-78, XP002109047, Washington, US, Scheme I; Tables I and II. |
A. Wissner: “Analogues of Platelet Activating Factor. 6. Mono- and bis-aryl Phosphate Antagonists of Platelet Activating Factor” Journal of Medicinal Chemistry, vol. 35, No. 9, May 1 1992, pp. 1650-1662, XP002109048, Washington, US, p. 1651, Scheme II, R=d. |
P. Sperling: “In vivo Desaturation of cis-delta-9-monounsaturated to cis-delta-9, 12-diunsaturated alkenylether glycerolipids” Journal of Biological Chemistry, vol. 268, No. 36, Dec. 25, 1993, pp. 26935-26940, XP002109049, American Society of Biological Chemists, Baltimore, MD., US, ISSN: 0021-9258, p. 26935, Abstract; Fig. 2. |
W.J. Baumann: “Reactions of Aliphatic Methanesulfonates. I. Syntheses of Long-Chain Glyceryl-(1) ethers”, Journal of Organic Chemistry, vol. 29, No. 10, Oct. 1964, pp. 3055-3057, XP002109050, Easton, US, Table II, Compounds XXI and XXII, p. 3057, col. 2. |
R. Mechoulam: “Identification of an Endogenous 2-monoglyceride, present in Canine Gut, that Binds to Cannabinoid Receptors” Biochemical Pharmacology, vol. 50, No. 1, 1995, pp. 83-90, XP002109088, cited in the application, p. 83-p. 84. |
Devane et al. Science 258: 1946-1949 (1992a). |
Wagner et al, Nature 390: 518-521 (1997). |
Varga et al. Eur. J. Pharmacol. 278: 279-283 (1995). |
Feigenbaum et al. Eur. J. Pharmacol. 169: 159-165 (1989). |
Mechoulam et al. The Therapeutic Potential of Marihuana, eds. S. Cohen, R.C. Stillman, Plenum Press, NY; pp 35-48. |
Avidor et al.; J. Biol. Chem. 271: 21309-21315 (1996). |
Rhee et al.; J. Med. Chem. 40: 3228-3233 (1997). |